

“Ultra-short Cell and Gene Therapy (CGT) process leveraging LNP technology”

Pantherna Therapeutics GmbH and TQ Therapeutics GmbH announce a research collaboration to advance both of their proprietary platform technologies to include LNPs into an ultra-short extracorporeal cell therapy process.

Pantherna Therapeutics GmbH, an mRNA-lipid nanoparticle (LNP) platform company dedicated to the research and development of innovative mRNA-based therapeutics team up with TQ Therapeutics GmbH, an advanced CGT company developing an ultra-short extracorporeal point-of-care process. The joint goal is to investigate novel strategies for combining both platforms on enhanced therapeutic cell generation. The efforts focus on exploiting the individual platform advantages regarding flexibility, safety and efficacy to obtain fast and cost-effective cellular therapies. Both companies believe that combining the point of care process with LNP technology will have a major impact in solving the current challenges in cell-and-gene therapy to make cell therapies scalable and broadly accessible for many patients.

"A collaboration of visionary teams is the cornerstone of innovation. In Pantherna Therapeutics, TQx has found a partner with whom we believe we can revolutionize cell therapies as they exist today. By uniting our technologies, we are creating a new platform for the production of CAR-T cells, making them accessible to everyone." - *Dr. Christian Eckert (CEO - TQ Therapeutics)*

"Pantherna is pleased to collaborate with TQ Therapeutics on their novel extracorporeal process for the generation of autologous CAR-T cell therapies. Our proprietary PTX-LNPs will serve as a non-viral delivery vehicle for this innovative approach. Together we aim to significantly advance cell therapy and provide new treatment options for patients." - *Dr. Ansgar Santel (CEO - Pantherna Therapeutics)*

Pantherna Therapeutics company summary:

Pantherna Therapeutics GmbH (Hennigsdorf, Germany) develops novel first-in-class therapies based on mRNA for indications with high medical need. Pantherna's therapeutic programs are based on two innovative and proprietary platform technologies, the mRNA expression constructs (PTXmRNA®) and necessary lipid nanoparticles (PTXΔLNP®) for cell type-specific expression of therapeutic proteins. Pantherna is pursuing the development of a pipeline of novel mRNA-LNP candidates that will enable the therapeutic use of mRNA in various tissues and cell types.

www.pantherna-therapeutics.com

TQ Therapeutics company summary:

TQ Therapeutics GmbH (Martinsried, Germany) is a biotechnology company dedicated to advancing the field of cellular therapies through innovative technologies. The company's mission is to develop a transformative cell processing platform, enabling advanced and affordable treatments in CGT. This technology will deliver highly individualized cell therapies directly to the patient's bed-side.

www.tqtherapeutics.com